Buzz Pocket: July 2021

Friday, July 30, 2021

Top Scenario: Therapeutic Obstructive Sleep Apnea Device Market Update | Increasing Investment Is Expected To Boost Market Growth

Global Obstructive Sleep Apnea Device market was valued at $ 4,661.6 Million in 2018 and is expected to reach of $ 9,561.3 Million by 2026, growing at a CAGR of 9.6% over the forecast period.

Obstructive sleep apnea is caused due to the blockage of the airways. This happens during sleep when the tongue folds with the soft palate and stops the air to pass on against the throat. It is being estimated that most of the mid age population tends to experience obstructive sleep apnea more than 5 times in half an hour.

Increasing number of cases in the sleep apnea is expected to drive the market for the therapeutic obstructive sleep apnea devices. It has been estimated that, around 80% of the patient who are suffering from obstructive sleep apnea are not being treated. The ratio between the total number of patients facing the obstructive sleep apnea and the patient who is being diagnosed is very minimal, so rising awareness among the patient can lead to the growth of the therapeutic obstructive sleep apnea market. Lack of awareness regarding the effects caused due to the obstructive sleep apnea such as, high blood pressure, diabetes, obesity and sometime the death of the patient may occur due to negligence and unawareness. Government initiative to raise the awareness among the people and the advanced technologies expected to give a boost to the overall obstructive sleep apnea therapeutic devices market.

The main reason for dissension of therapeutic obstructive sleep apnea devices is due to the lack of acceptance from the patients, this is mainly due to the discomfort and anxiety caused by the mask. The cost of therapeutic obstructive sleep apnea devices market is very high as compared to the other sleep apnea disease. The cost is the main constraint for the increase of the therapeutic obstructive sleep apnea devices market.

Depending on the type the positive airway pressure segment held the largest market size in 2018 for $2,187.8 million and is expected to reach $4,542.3 million by 2026, at a CAGR of 9.7%. Positive airways reduce the sleep apnea occurrence and protect the airways from closing. The oral application is estimated to grow at 9.5% CAGR by generating revenue by $1,768.2 million by 2026. It is expected to offer patient with greater satisfaction. Oral applications are portable, flexible and easy to use, so American Academy of Sleep Medicine (AASM) suggested to wear oral application with severe obstructive sleep apnea, who cannot wear and use positive airway pressure.

Due to the rising number of hospitals and growing investment in healthcare the hospitals and sleep laboratories segment is anticipated to drive the market over the forecast period. Hospitals and sleep laboratories segment accounted for $2,569.3 million in 2018 and is expected to rise at a CAGR of 9.4% in the forecast period.

North America holds the largest market share for the therapeutic obstructive sleep apnea devices market. This region registered 10.2% CAGR and is anticipated to generate a revenue of $3,970.7 million by 2026. The Asia-Pacific is the largest growing market for the therapeutic obstructive sleep apnea devices as most of the Asian countries are not developed in the medical facilities and are unaware of the therapeutic obstructive sleep apnea devices. It is projected that the region sleep apnea devices market is expected to grow at $1,777.7 million by 2026 at a CAGR of 9.0%.

The major key players in the therapeutic obstructive sleep apnea devices market are Invacare Corporation GE Healthcare, Compumedics Limited, BMC Medical Co., Fisher & Paykel Healthcare, Cadwell Laboratories Inc., Ltd, Braebon Medical Corporation, Becton Dickinson (CareFusion Corporation), Curative Medical Inc., ImThera Medical, Inc.

Contact Us:

Mr. Abhishek Paliwal
Research Dive
30 Wall St. 8th Floor, New York
NY 10005 (P)
+ 91 (788) 802-9103 (India)
+1 (917) 444-1262 (US) Toll
Free : +1 -888-961-4454
Email: support@researchdive.com
LinkedIn: https://www.linkedin.com/company/research-dive
Twitter: https://twitter.com/ResearchDive
Facebook: https://www.facebook.com/Research-Dive
Blog: https://www.researchdive.com/blog
Follow us on: https://covid-19-market-insights.blogspot.com

Industry Verticals: Breast Implant Market – Latest and updated Scope and Application 2020-2027

Breast Implant Market size will exceed $4.9 Billion by 2026, growing at a CAGR of over 10.3% from 2019 to 2026; according to a new research study by Research Dive.

An increase in the number of breast augmentation processes, along with the rise in breast cancer incidences across the world will significantly drive the global breast implant market size over the forecast period. The breast augmentation processes enable women to improve their breast size, and also to improve their hip contour balance. These are also called as reconstruction procedures, which help to restore the breasts’ size to near normal size. They also help in improving the appearance of the breasts. Rapid growth in these procedures will significantly spur the global breast implant market growth during the projected timeline.

Rapid growth in the incidences of breast cancer across the world will boost the growth of breast implant market growth in the coming years. As a result of this, the majority women are preferring mastectomy procedures during their breast cancer treatment.

However, the high cost of implantation procedures, coupled with the rising implications post-surgeries will impede the breast implant market growth.

The silicone breast implant market size held the largest share in 2018 and is projected to grow at a CAGR of over 10.2% over the projected timeframe. The dominant market size is expected throughout the forecast period, owing to the product’s capability to look natural. Some of the other benefits such as reduced wrinkling will further provide a significant boost to product adoption.

The breast implant market for reconstruction procedure will increase at a CAGR of more than 10.7% during the projected period. This is majorly due to the increasing incidences of breast cancer, and also to avoid them. An increase in awareness about reconstruction surgery to overcome the cancer incidences has resulted in significant growth in procedure adoption.

The majority of the patients are preferring clinics as their place of surgery. This is majorly due to the presence of skilled professionals, coupled with the less cost associated with the comparison with the hospital sector. Breast implant procedures in clinics will grow at a CAGR of over 9.8% during the projected period. Expanding infrastructure in the healthcare sector in the emerging economies will further enhance the market growth. This segment will further grow on account of the availability of skilled plastic surgeons in the clinics.

North America market held a significant market share in 2018 and accounted for more than 40% in 2018. An increase in the number of the female population preferring the augmentation procedures will further drive the market growth. Growth in per capita expenditure, coupled with the rise in disposable income will further serve to be one of the high impacting factors for the growth of North America breast implant market growth.

The Asia-Pacific market is projected to witness a robust growth at 11.0% CAGR during the forecast period. The rise in the number of hospitals and clinics offering plastic surgery procedures, coupled with the increase in the number of plastic surgeons in this region will enhance the regional market growth during the coming years.

Some of the prominent companies in the global breast implant market include GC Aesthetics, Allergan, Mentor Worldwide LLC, Laboratoires Arion, Groupe Sebbin, Hansbiomed Co. Ltd., Sientra Inc., Silimed, Groupe Sebbin SAS, and CEREPLAS among many others. Some of the strategies preferred by the operating companies are product development and acquisitions.

Contact Us:

Development Trends: What Makes Autotransfusion Devices Market Outperforming Its Substitutes?

According to a recent report published by Research Dive, titled, “Autotransfusion Devices Market by Type, and Application: Global Opportunity Analysis and Industry Forecast, 2018-2027,” the global autotransfusion devices market size was $1,121.5 million in 2018, and is anticipated to reach $1,939.7 million by 2027, at 6.5% CAGR from 2019 to 2027.

The North America regional market dominates the global market, followed by Europe, Asia-Pacific, and LAMEA. U.S. dominated the global autotransfusion devices market share in 2018, and is expected to grow at a significant rate during the forecast period.

Autotransfusion is a process wherein a person receives their own blood for a transfusion, instead of banked allogenic (separate-donor) blood. There are two main kinds of autotransfusion: Blood can be autologously “pre-donated” (termed so despite “donation” not typically referring to giving to one’s self) before a surgery, or alternatively, it can be collected during and after the surgery using an intraoperative blood salvage device (such as a Cell Saver or CATS). The latter form of autotransfusion is utilized in surgeries where there is expected a large volume blood loss – e.g. aneurysm, total joint replacement, and spinal surgeries. The device used for autotransfusion is called autotransfusion devices. Presently, many surgeons utilize autotransfusion innovatively such as with a cell processing step which not only is efficient and less time consuming but also enables the patient to have safe blood transfusion. Moreover changing lifestyles coupled with the increasing obesity amongst the masses has resulted in increased chances of having cardiac diseases which has prompted the growth of Autotransfusion devices.

High occurrence of cardiac diseases leads to the huge demand of auto-transfusion device across the world. Furthermore, absence of any risk of transfusion or transmitted infections is boosting the growth for autotransfusion devices globally. On the contrary, inability to separate contaminants from blood is expected to be a major restraint for autotransfusion devices market. On the other hand, growing Adoption of whole body autotransfusion devices.

Off-Pump Autotransfusion devices holds the highest market share amongst the product type segment and is expected to grow with a CAGR of 6.6% during the forecast period 2019-2027. The driving factor for off-pump transfusion is the device usage ease, coupled with no blood loss feature during the transfusion process. Major trends in the off-pump transfusion is its efficacy and the fact that off-pump transfusion have much lower post-operative morbidity and mortality especially in high risk patients.

Amongst the end use segment, Hospital segment holds the largest market share and is expected to grow at CAGR of 6.6% during the forecast period. This primarily because, the hospitals have specialized departments wherein blood transfusion is required as such the autotransfusion devices are required in multiple numbers to cater to various transfusion requirements of specialized diseases in various department.

North America has the highest market share for autotransfusion device globally and is expected to grow at a healthy rate of 6.4% over the forecast period. U.S, hold the majority of the share of the North America market and it is one of the leading countries globally. As the regulatory standards regarding transfusion are quite stringent in U.S., companies are investing a lot on Research & Development for approvals of commercial sale of Autotransfusion device and therefore they are focused on quality and innovative products so as to efficiently handle the process and edge ahead of competitors, thus driving the growth of Autotransfusion device in the country.

One of the prominent players in autotransfusion devices market viz., Medtronic plc announced it has received Breakthrough Device designation from the U.S. Food and Drug Administration (FDA) for its Personalized Closed Loop (PCL) insulin pump system, currently in development. The PCL technology is designed to automate insulin delivery in a way that is real-time, personalized and adapts to the user. The system will also provide insights and predictive diagnostics unique to the individual, with a goal of dramatically simplifying diabetes management for the patient. The recent acquisition of Nutrino Health and their expertise in nutrition data science will play a key role in the accelerated development of this breakthrough technology. Zimmer Biomet Holding, Becton Dickinson and Company, LivaNova, Plc, Teleflex Incorporated, Stryker Corporation, Fresenius Medical Care AG & Co. KGaA, Terumo Corporation, Haemonetics Corporation and Getinge AB.

Contact Us:

Emerging Trends: Why Dynamics of Animal Parasiticides Market Is Changing Drastically? What If History Is Any Guide?

According to a new report published by Research Dive, the global animal parasiticide market forecast will be $7,082.2 million by 2026, rising from $5,096.0 million in 2018, and at 4.2% CAGR.

The significant animal parasiticide market drivers; are increasing the adoption of pet animal’s and awareness about the importance of parasiticide products to prevent zoonotic diseases. Increasing knowledge among the people about livestock and livestock healthcare, rising the concerns to control of zoonotic diseases in the animals and livestock is anticipated to lead the market growth in the future time. Additionally, increasing investments to develop improved parasiticide products for veterinary healthcare and rise in the expenditure on animal healthcare are further enhancing the animal parasiticide market growth in a positive manner. Parasiticide product cost and heavy R&D investments are projected to hamper the global animal parasiticide market. Animal parasiticide market advancements and rise in the government implementations to prevent the animal and livestock health are expected to generate major opportunities for the new entrants into the market in the coming years.

Ectoparasiticide type market will witness a significant growth and is estimated to generate a revenue of $1,678.5 million, at a 4.6% CAGR over projected period. The rise in the demand of ectoparasiticides type to prevent or control parasite insects in animals is anticipated to boost the market growth in the coming years. Endectocides type dominated the global animal parasiticide market, it is registered for $2,293.2 million in 2018, and is projected to account for $3,109.1 million by the end of 2026. This is due to endectocides are major veterinary parasiticide that are used for the treatment of arthropods and nematodes insects affecting animals. Additionally, increase the use of endectocides to minimize parasites diversity is expected to drive the animal parasiticide market in the projected period.

The companion animals segment is expected to experience the substantial growth, it is estimated to register of $2,323.0 million, growing at a highest rate of 4.5% in the projected time frame. This is owing to the growing requirements from pet owners and veterinary centers to prevent or treat animals from the zoonotic diseases. Additionally, rise in the animal healthcare expenditure and number of pet owners are expected to enhance the animal parasiticide market over forecast timeframe. The farm animals segment has registered the highest animal parasiticide market share of 68.0% in 2018, and is estimated to generate revenue of $4,759.3 million, growing at 4.0% CAGR over projected period. This growth is attributed to high quantity requirement of parasiticides, due to huge quantity of farm animals present across the globe.

Asia-Pacific market is projected witness a noteworthy growth rate, it is projected to account for $ 1,614.8 million and at a CAGR of 4.7% in the projected time period, owing to upsurge in the adoption of animals, and increase in the product demand from the quality meat consumers across the region. Additionally, rising awareness about the importance of parasiticides to control the diseases will further drive the market growth in the coming years. North America market is accounted for the highest animal parasiticide market size of $1,885.5 million in 2018, it is estimated to register of $2,556.7 million and at a 3.9% CAGR, owing to rising interest of pet animals owning among the people.

Elanco, Boehringer Ingelheim animal Health, Ceva Santé Animale, Vetoquinol, Eli Lilly, Bayer AG Zoetis Inc., Sanofi, Merck Co., and Perrigo Company Plc, are some of the animal parasiticide market players. These manufacturers are accepting the key approaches such as product infections, collaboration and partnerships in order to rise their market size in the global animal parasiticide market. For example, in September 2019, Zoetis Inc. presented positive effectiveness of triple combination of parasiticide at American Heartworm Society Meeting, which is useful for preventing animals from heartworm disease and to control and treat of fleas, intestinal and ticks in dogs.

Contact Us:

Opportunities: Intrathecal Drug Delivery System Market Outlook: World Approaching Demand & Growth Prospect 2019-2025

According to a study of Research Dive, intrathecal drug delivery system market forecast shall surpass $1662 Million by 2027, registering a CAGR of 7.2% from 2019 to 2027.

Intrathecal drugs delivery (IDD) system plays the important role in the treatments of intractable (uncontrollable) pain. IDD system utilized for selected patients which are associated with major reduction in quality of health and that have not options of other treatment. This treatment requires highly specialized team for ensuring appropriate selection along with the safety criteria.

IDD enables therapist to formulate individualized treatment regimens which can provide improved analgesia with small doses coupled with fewer adverse effects over opioid-based therapies.

The major factors that boost the global intrathecal drug delivery system market growth are rising demand for intrathecal drug delivery system for cancer pain. In addition, surge in cost-effective cancer pain treatment using such systems are expected to boost the market growth during the forecast period. However, complications of ITDD systems hamper the growth of the intrathecal drug delivery system market.

Externalized and Connected with a pump holds the highest market share amongst the product type segment and is expected to register revenue of $1,358.6 million during the forecast period 2020-2027 at a CAGR of 6.8%. Externalized and connected with a pump is used in situations wherein there’s frequent need of change of catheter such as those who are suffering from cancer. They are in trend as they are cost effective compared to fully implanted systems.

These pumps have proved to be very effective for cancer pain and have been use since the last 3-4 decades and they are still in use as fully implanted systems are still in R&D phase and are not use in major developing countries.

Amongst the Application segment, Spasticity Management for intrathecal drug delivery system market size, generating revenue of $635.1 million in 2018, and is expected to grow at CAGR of 7.1% registering revenue of $1,140.2 million by 2027. ITDD devices are mostly used for spasticity management and with advent of programmable system the spasticity can be managed by controlling the flow of drug delivery. They are majorly used in European countries like Belgium, Germany, UK and others. These systems have opportunities in the developing countries wherein the spasticity problems are more pronounced.

North America has the highest Intrathecal drug delivery system market share globally and is expected to register revenue of $695.9 million growing at a healthy rate of 7.4% over the forecast period. Due to ease usage which signifies better control and long lasting nature of the Intrathecal devices North America market has highest market share for implanted Intrathecal drug device Therefore, it is one of the significant factor for growth of Intrathecal drug devices market.

U.S, hold the majority of the share of the North America market and it is one of the leading countries globally. Companies are spending heavily on research & Development activities, in order to provide innovative and effective pain management solution thereby driving the growth of Intrathecal Drug delivery systems in the country.

Prominent players in Intrathecal Drug Delivery Systems are Medtronic plc is one of the potential manufacturers of programmable intrathecal drug Delivery Systems has successfully launched the Medtronic SynchroMed II (drug infusion pump), which is utilized to deliver drug into a patient’s body. The pump is used together with a catheter to deliver a specific drug to the patient’s spinal fluid. Other major players include Flownix Medical Inc, Teleflex Incorporated, DePay Synthes, Tricumed Medizintechnik GmbH, Smiths Group Plc, Summit Medical Group, B Braun Melsungen AG, Becton, Dickinson & Company and Fresenius Medical Care AG & Co. KGaA.

Contact Us:

In-Depth Analysis: Why Medical Marijuana Market May Skyrocket: Study Revealed Which Players May Turn Game?

As per study of Research Dive, medical marijuana (cannabis) market forecast revenue of $36,205.4 million in the year 2026 growing at CAGR of 28.7%.

Marijuana is more safe and has less severe side effects over other treatment options such as opioid-based treatments. It is more efficient in reducing nausea and also improving appetite among chemotherapy patients. Increasing cancer burden along with rising demand for chronic pain management & treatment is projected to drive the medical marijuana market growth. For instance, as per publication of the World Health Organization (WHO), in 2018, Cancer disease is the second leading cause of death cases, in which Lung, breast, prostate, liver, stomach and colorectal cancer are the common types of cancerous diseases. Moreover, R&D activities, Clinical trials along with commercialization of cannabis are anticipated to boost the global medical marijuana industry. However, stringent government regulation, lack of awareness in the emerging countries and absence of proper information shall restrain the medical marijuana market growth. China has the significant opportunities for the medical marijuana market; this is majorly due to China is primarily involved in the research and also it has heavy production of marijuana. Moreover, key players such as Hanma Investment Group received permission to extract CBD (Cannabidiol) in China. Currently this company exports 90% of its production, to the countries such as, Germany, the U.K., and the US.

Pain management segment shall generate revenue of $15,133.9 million in 2026, increasing at a CAGR 28.2%. Pain management segment is broadly classified into neuropathic pain, cancer pain, and others. Rising prevalence of cancerous diseases attributed to primarily increase the necessity of pain management across the globe is anticipated to foster the global market.

Inhalation segment shall generate revenue of $25,162.8 million by the end of 2026, at a CAGR of 28.1% till 2026.This segment has enormous opportunities due to properties such as reduction in noxious emissions and quick effects. Topical segment shall generate revenue of $7,965.2 million by the end of 2026, at a CAGR of 30.2% till 2026.

Online segment will see enormous growth owing to, easy accessibility and significant changes in the legality of marijuana attributed to increasing need of E-commerce payment system in cannabis market will generate revenue of $9,558.2 million by the end of 2026, rising at a CAGR 32.3%. Dispensaries segment is expected to generate revenue of $26,647.2 million by the end of 2026, growing at a CAGR of 27.6%.

North America medical marijuana market size will cross $11,404.7 million in 2026, increasing at a CAGR 26.6%. North America marijuana market is anticipated to increase at fast rate owing to legalization of medical marijuana in Canada, in addition, extensive growth in cannabis based products for medicinal use and legalization of cannabis by the House Judiciary Committee in the US is expected boost the market in this regions.

Medical Marijuana market share for Asia-Pacific region is projected to grow at a CAGR of 30.8% by generating a revenue of $8,037.6 by 2026. Asia Pacific region is projected to witness significant growth owing to the piecemeal legalization of medicinal cannabis in the nations such as Australia and Israel. Additionally, Thailand is the nation that has fully legalized medicinal marijuana with multiple clinical applications.

Some of the significant medical marijuana market players are: mCig, Emerald Health Therapeutics, ABcann Medicinals, Inc., Insys Therapeutics, Inc., Aphria, Inc., Cannabis Sativa Inc., Canopy Growth Corporation, GW Pharmaceuticals, Green Relief Inc., and Aurora Cannabis, Inc. These players are initiating various steps in order strengthen their presence such as merger & acquisitions, new product development. For example, to meet the demand of rising number of patients, Green Relief Inc., a licensed manufacturer of marijuana based therapeutic medicines, has officially acquired a new facility department in Canada.

Contact Us:

Challenges: What Portable Oxygen Kit Market Is Aiming Next: Leveraged Returns Or Disaster?

According to a new report published by Research Dive, the global portable oxygen kits market was accounted for $1,372.6 million in 2018, is projected to reach $2,616.8 million by 2026, and at 8.4% CAGR.

Growing awareness among the people about prevalence of chronic obstructive pulmonary disease (COPD) and importance of portable oxygen kits while mountain climbing and participating in adventure activities are key drivers for the portable oxygen kit market growth. As per publication of American Academy of Allergy Asthma and Immunology, around 0.255 million people are suffering with respiratory problems in the world, and is anticipated to increase day by day, due to this, the demand for portable oxygen kit is increasing to diagnose the patients. Furthermore, rising demand of portable oxygen kits from aerospace & automotive industry for drivers and pilots to deliver constant oxygen source in the disaster sites and high speed vehicles is expected to drive the market growth over the projected period. Furthermore, rising the usage of portable oxygen kits in the hypoxic zones (where the oxygen levels are very low) is anticipated to increase the demand of portable oxygen kits. Shortage of portable oxygen kits and cost of the oxygen kits are major restraint factors for the market growth.

Based on end use, the home applications segment will witness a noteworthy growth, that is anticipated to account for $1,058.8 million, and increasing with a rate of 8.9% in the projected period. This growth is majorly due to increasing usage of portable oxygen kits in the homes. This portable kits can provide oxygen when the consumer needs addition oxygen supply and regular usage of these kits can minimize the risk of death from low levels of oxygen, due to this, the consumers are utilizing oxygen kits in homes instead of running to the hospitals. Healthcare segment dominated the overall market, and registered a revenue of $590.2 million in 2018, and is estimated to account for $1,125.5 million, at 8.4% CAGR over projected time.

Asia Pacific region market is expected to experience significant growth during the projected time, owing to advancements in healthcare sector. Furthermore, increasing the portable oxygen kits in home application and defense sectors is projected to boost the Asia-Pacific region market growth over projected period. The Asia-Pacific market is anticipated to generate revenue of $782.8 million, and growing with highest CAGR of 9.3% during projected timeframe.

North America region held highest portable oxygen kit market share of 45% in 2018 and is anticipated to continue its dominance over forecast timeframe. The dominance is owing to well established healthcare infrastructure in the region. Moreover, the existence of key manufacturers and increasing the awareness about advanced treatment for COPD related diseases are further anticipated to boost the market growth in North America region, owing to the market is estimated to account for $1,1776.6, at a CAGR of 8.4% in the projected time.

Teijin Limited, O2 Concepts, Chart Industries, Invacare Corporation, Inova Labs Inc., Inogen Inc., Worthington Industries, NIDEK Medical Products Inc., Koninklijke Philips N.V., and DeVilbiss Healthcare, are some of the major portable oxygen kit market players in the world. The manufacturers are implementing key approaches such as joint ventures, product inventions, new product developments, partnerships and collaborations to rise their position in the global market.

Contact Us:

Advancement: Know the Rapid Growth Factors of Healthcare Gamification Market| Stay Up-To-Date With Emerging Trends Ahead

The healthcare gamification market share is predicted to grow at a CAGR of 11.9% by generating a revenue of $47,281.5 Million by 2026.

Gamification includes applying the techniques used in game, mechanics of game, and game style in non-gaming applications to engage the audience and make the dull task into more fun and engaging. Basically it is an application of elements in video games, which helps to solve the everyday problem and enables the user to change the behavior, develop skills and enable innovation in health care. The goal of the gamification is to change the behavior of the patient. The increase in the wearables and health & wellness app with gamification is the strong sign that the people are liking it.

The increase in the usage of digitalization and the technology adoption are expected to drive the healthcare gamification market. Many companies are using the digital platform for the people to check their health data. For instance, Pokémon go helped the players to increase the step count of the user, consciously or unconsciously which helps in making them fit without knowing them. By the use of such application, it provides offers and rewards to keep self-motivated and keep a check on their health. So, digitalization and adoption of such technologies is predicted to upsurge the market.

Improper use of these games and training programs is considered to be the biggest restrains for market. These gamifications are programmed in such a way that it can help to attain the objective. But these gamifications are used only for fun purpose and once the desire is being fulfilled then they lose interest on these devices and applications which can hamper the growth of the market in the forecast year.

Casual game is held the largest market share of 42% in the type segment. Causal game is forecasted to grow at a CAGR of 10.2 by generating a revenue of $17,541.5 million by 2026. Casual games are usually build to monitor the user’s behavior and provide necessary therapy.

Prevention accounted for the highest growth rate in the application segment. Rise in the fitness enthusiast with the availability of several app and devices is expected to drive the market for prevention. Prevention application was $4,231.3 million in 2018 and is anticipated to generate a revenue of $11,584.0 million by 2026.

Depending on the end use the market is segmented into consumer based and enterprise based. Enterprise based accounted for the highest growth rate of 15.7% over the forecast period, at $5,577.6 million in 2018. Due to the various benefits offered by the employer the employees are the participation in gamification events has grown considerably in the recent years.

Depending on the region the market is segmented into Asia-Pacific, North America, Europe and LAMEA. Asia Pacific accounted for the highest market share of 32.0% in 2018. Asia pacific is predicted to grow at a CAGR of 11.0% by generating a revenue of $14,184.5 million by 2026. Due to the rise in the population and lesser medical facilities is expected to drive the market for this region.

Key competitors in the market are Mango Health, JawBone, Nike, Hubbub Health, EveryMove, Akili Interactive labs, Bunchball, Microsoft, Ayogo Health, and Fitbit among others. Mango health have developed a new gaming application which rewards patients with points every time they set reminder alerts for the medicine consumption.

Contact Us:

Antiviral Therapies Market Is Projected to Grow at a Substantial Rate by 2027

Global Antiviral Therapy Market size is expected to grow with a CAGR of 5.8% from 2019 to 2026 According to a study conducted by Research Dive. The global antiviral therapy market size was accounted at $48.1 billion in 2018 and is anticipated to garner $ 75.6 billion by 2026.

Increasing incidences of viral infections, growing awareness among public about these infections, rise in healthcare spending, growing R&D investments, and growing incidences of severe and deadly disorders in people are the key antiviral therapy market drivers responsible to boost the growth of global market during estimated period. In addition, development of broad-spectrum antibiotics and surge in profitable opportunities in the developing economies of Asia-Pacific and LAMEA regions are expected to provide numerous opportunities for the growth of the market. On the other hand, huge costs involved in the manufacturing of these therapy and rise in the demand for alternative medicines such as homeopathy and naturopathy are expected to restrain the development of the market.

The HIV segment in the antiviral therapy market was valued at $16.4 billion in the year 2018 and is expected to increase with a growth rate of 5.4% throughout the estimated period. This is because of the rising occurrence of HIV infection across the globe. The majority of HIV antiviral drug usage has been seen in the North America region. Also, the consumption of antiviral therapy in African region is expected to increase and fuel the development of the market.

The online pharmacy segment is expected to grow at an increased speed by generating a revenue of $23.2 billion by the end of 2026, at a significant growth rate of 6.1% during the forecast period. On the other hand, the hospital pharmacy segment is anticipated to dominate the market by generating a revenue of $35.5 billion by the end of 2026, at a substantial growth rate of 5.5% throughout the forecast period. This is mainly due growing trends in the online shopping sector in the developed and developing countries. At present, the market share is mainly controlled by a few top pharmaceuticals as well as biotechnology companies.

Regionally, the market has been studied across Asia-Pacific, North America, Europe, and LAMEA. Asia-Pacific antiviral therapy market is anticipated to grow at an increased pace with a healthy growth rate of 6.5% during the forecast period, garnering $12.8 billion by the end of 2026. This is mainly due to factors such as the growing cases of HIV infection, growing awareness about HIV infection, and increasing collaboration between public and private sectors in this region. Furthermore, the North America antiviral therapy market held a leading position in the global antiviral therapy market in 2018. This region is anticipated to hold its lead position in the market throughout the forecast period by generating a revenue of $29.5 billion by 2026. This is attributed to factors such as the rising occurrence of HIV and hepatitis C infections, well-established market players in the region, growing healthcare awareness, rising elderly population, and increasing healthcare spending in this region. On the contrary, factors such as patent expiration and generic erosion of antiviral therapy are hindering the growth of the market in this region.

The key market players profiled in the report are F. Hoffmann-La Roche Ltd., Gilead Sciences, GlaxoSmithKline, Abbott Laboratories, AbbVie Inc., AstraZeneca Plc., Bristol- Myers-Squibb, Johnson & Johnson, Schering-Plough Corporation, and Merck & Co., Inc. These market players are undertaking several activities to grab a major share of the market and hold a leading position in the antiviral therapies industry. Some of these activities include new product launches, mergers and acquisitions, antiviral therapy market developments in current technology. These are some of the growth strategies implemented by these market players.

Contact Us:

3D Cell Culture Market 2020 to Witness Excellent Long-Term Growth Outlook

According to a study of Research Dive, global 3D Cell Culture market forecast shall cross $12,638.8 million by 2026, growing at a CAGR of 29.4 during forecast period.

3D Cell culture is an essential tool in clinical analysis and biological science. It has multiple applications such as in biosensors, drug screening and others. Many improvements have been made in automated high-throughput cell culture systems. Increasing demand for regenerative medicine and economic drug discovery is expected to drive the demand for the 3D cell culture market. 3D cell cultures are primarily used to observe the abnormal behavior of cells and the cell-cell interaction. Furthermore, 3D cell culture systems play a significant role in the development of precision medicine and personalized medicine. For instance, as per study of cancer researchers (University of Michigan) newly invented 3D structure could enable physicians to test medications on model tumors grown from a patient’s own cells. These advances are projected to boost the growth of global cell culture market. However, more complex culture system, added expenses and threats from substitutes like 2D cell cultures are projected to limit the 3D cell culture market growth.

With new advances, 3D composite scaffolds have many versatile properties. It will be tremendously useful to develop treatments for nerve disorders and spinal cord injury (SCI) by taking help of cell transplantation methodologies and biomaterials. The most remarkable advantage of 3D cell culture is, their properties can be easily adapted by modifying the structure and composition. These key factors of 3D cell culture are projected to create enormous opportunities for the growth of 3D cell culture industry.

According to Analyst Evaluation, Microchips market shall register a revenue of $2,515.5 million by the end of 2026, growing at a CAGR of 30.1% during the forecast period; this is significantly due to new advances in 3D culture ‘organs-on-chips’. Organs-on-chips allow study of human physiology and also reveal development of novel in vitro disease models. It could provide potential replacements for animals used in toxin testing and drug development. These advancements are anticipated to grow the demand of microchips in global market, and are projected to boost the global market. Scaffold-based platforms have the largest market share and this segment will register a revenue of $3,425.1 million by the end of 2026, growing at a CAGR of 28.4%. Scaffolds can be significantly used in drug development therapeutic or specialty areas; which is anticipated to fuel the of global market growth.

Based on applications, the market is segmented into Stem Cell research, drug discovery, cancer research, and regenerative medicine. 3D cell culture market size for cancer research will generate a revenue of $4,057.1 million by 2026, growing at a CAGR of 28.5% throughout the forecast period; this is majorly due to various types of cancers such as breast cancer, lung cancer and others being dominant among the population. Cancer has a pervasive prevalence across the globe, which has led to rise in demand for cancer research, which is further attributed to boost the demand for 3D cell culture market. 3D cell culture market for regenerative medicine will register a revenue of $3,690.5 million by 2026, growing at a CAGR of 30.1%. Many developed and developing countries such as Japan is focusing more on contract manufacturing tie-ups, and continues to be a lucrative place for biotech ventures to do business. Japan is the world leader in regenerative medical products; these key strategies of the government are anticipated to spur the growth of 3D cell culture market.

3D cell culture market for biotechnology & pharmaceutical companies will register a revenue of $5,184.4 million by 2026, growing at a CAGR of 28.9% during the forecast period; this is majorly due to huge developments in the laboratory, technology and operations. Furthermore, rising pressure on sales of established treatments, rapid growth of cell therapies and focus on advanced manufacturing and technologies are the factors expected to grow the market.

North America 3D Cell Culture market size will cross $4,019.1 million by 2026, increasing at a healthy CAGR of 28.1%.

Heavy investments in research & development, high healthcare expenditure, and extensively increasing number of cancer cases are considered to be one of the driving factors that are booming the growth of North American market.

3D Cell Culture market share for Asia-Pacific region is expected to rise at a CAGR of 30.7% by generating a revenue of $3,020.7 million by 2026. The market growth in the region is increasing drug discovery initiatives among pharmaceuticals and biotechnology companies in the region. Major economies such as India, Singapore, Japan and South Korea are emphasizing more on public sector openness to partnership with established companies. For instance, leading market players such as Bayer, GlaxoSmithKline and AstraZeneca are collaborating with Singapore partners across drug discovery.

The major 3D Cell Culture manufacturers include QGel SA, Hµrel Corporation, SynVivo, Greiner Bio-One International, Advanced BioMatrix, Lonza, Corning Incorporated, Thermo Fisher Scientific, TissUse GmbH, 3D Biotek. Players using updated technologies for their 3D Cell Culture will have good probability of having success in the rapidly blooming market. For example, Lonza has innovated the RAFT 3D Culture System that produces hepatocytes with increased stability and stronger cytochrome responses.

Contact Us:

Medical Tourism Market Is Expected To Grow with a Healthy CAGR During 2020-2027

Traveling to overseas for affordable and state-of-the-art medical care and treatment is basically termed as medical tourism. Years back, people from developing countries used to travel to highly developed countries seeking advanced and safer treatment, which was barely available in their own countries. Today, people from developed countries travel to developing countries for cost-effective medical treatments, which has slightly changed the traditional concept of medical tourism.

The medical tourism market share is predicted to rise at a CAGR of 12.4% and is expected to reach $149.34 Million till 2026. Earlier, in 2018, market was valued $58.62 Billion.

Medical tourism means when a person travels to the other country to undergo a treatment. This is usually done by the patient when the medication is more expensive in their respective country or due to the unavailability of advanced medication and machinery in their home country. Basically, medical tourism is the combination of medical treatment and travel at the same time. It means that one travels to another country for medical purposes spending a few days abroad and combines a vacation with the medical procedure.

For More Detail Insights, Download FREE Sample Copy of the Report at: https://www.researchdive.com/download-sample/75

The high cost of treatment in the home country and the availability of advanced medical facilities in the developing countries is predicted to drive the medical tourism market. Affordability and convenience of the good medical facilities with the guidance from the tourism department is expected to drive the medical tourism industry. For instance, in the U.S the cost spend for heart surgery will be almost 80% more than the total cost spends in Asian countries. So, due to these factors, many developed countries patients are preferring to get treated in the developing nation or the nation with high medical facilities with lesser cost for the treatment; these factors are predicted to boost the global medical tourism industry.

Private healthcare is expensive and many insurance companies don’t cover the insurance. There are many circumstances the patient has to face with regards to their insurance policy and regulation. For instance, insurance may not be covered by the company if the treatments are carried out overseas; if the insurance is covered then the insurance companies don’t pay the airfare and extra expenditures. Due to reimbursement policies, patients are forced to stay at their home country and get treated which is consider to be the major restraint for the medical tourism market.

Connect with Our Analyst to Contextualize Our Insights for Your Business: https://www.researchdive.com/connect-to-analyst/75

On the basis of the service type, medical tourism market size for Cosmetic segment is projected to generate a revenue of $31,063.9 million by 2026 with a CAGR of 11.9% in the forecast period. The curiosity of people to look different and change their appearance to keep themselves confident is predicted to boost the cosmetic treatment segment in the forecast period. Cancer treatment is projected to have the highest growth rate in the estimated period. The Medical tourism market share for cancer treatment is estimated to rise at a CAGR of 14.2% by generating a revenue of $7,616.6 million by 2026. The rise in occurrences of cancer worldwide is estimated to boost the cancer treatment segment. The treatment of cancer takes a lot of time, and patients prefer going outside their home country for their treatment due to better medical amenities with lesser cost. Medical tourism market forecast that cancer treatment segment in medical tourism market is going to experience a boost the in the forecasted period.

Based on the region segmentation Asia-Pacific has the highest growth rate. Asia-Pacific region is estimated to rise with a CAGR of 12.2% by generating a revenue of $54,452.9 million by 2026. The Asia-Pacific region provides all the medical amenities at a reasonable price so that the patient can afford it and can be cured. Due to the tourism friendliness and government policies with regards to tourism not being that strict, patients prefer the Asia-Pacific region to get them treated. These factors will boost the medical tourism market in this region.

The major key companies in the market are Prince Court Medical Centre, Aditya Birla Memorial hospital, KPJ Healthcare Berhad, UZ Leuven, Apollo Hospitals Enterprise Ltd, Fortis Healthcare, NTT Medical Centre, Asklepios Kliniken GmbH, Bumrungrad International Hospital, KPJ Healthcare Berhad and Asian Heart Institute among others.

Contact Us:

Mr. Abhishek Paliwal
Research Dive
30 Wall St. 8th Floor, New York
NY 10005 (P)
+ 91 (788) 802-9103 (India)
Free : +1 -888-961-4454
Email: support@researchdive.com
LinkedIn: https://www.linkedin.com/company/research-dive
Twitter: https://twitter.com/ResearchDive
Facebook: https://www.facebook.com/Research-Dive
Blog: https://www.researchdive.com/blog
Follow us on: https://covid-19-market-insights.blogspot.com

Activated Partial Thromboplastin Time Test Market Anticipated for Progressive CAGR Growth During 2020-2027

The global activated partial thromboplastin time test market forecast will surpass $601.2 million by the end of 2026, at a CAGR of 6.8%, and has been rising from $353.0 million in 2018, according to Activated Partial Thromboplastin Time Test Market Analysis by Research Dive.

Activated Partial Thromboplastin Time Test Market Trends: Rise in the prevalence of cardiovascular diseases coupled with increase in the demand for thromboplastin test instruments the key drivers for the growth of the activated partial thromboplastin time test market Increase in the adoption of thromboplastin test in the point-of-care diagnostic centers and improvements in the healthcare infrastructure are projected to drive the market growth. The improvements in healthcare infrastructure support the accessibility of test instruments and easy available of coagulation testing devices is anticipated to boost the activated partial thromboplastin time (APTT) test market growth. Furthermore, there is a rise in the blood disorders with increasing age of people across the globe; they require regular blood check-up to determine common and intrinsic pathways of blood coagulation. Due to wide usage of APTT test devices, the market is projected to grow in the coming years. Price of the treatment test coupled with dearth of skilled personal to perform APTT test are expected to hinder the growth of the market. Technological improvements in the activated partial thromboplastin time (APTT) testing instruments and key manufacturers concentrating on mergers & acquisitions to minimize the devices cost is anticipated to create ample investment opportunities in the activated partial thromboplastin time test market.

Download FREE Sample Copy of the Report at: https://www.researchdive.com/download-sample/79

Instruments type segment will witness a noteworthy growth during the projected time. The growth is majorly because companies are increasing the R&D activities on diagnostic instruments to improve performance and accuracy of the instruments with low cost. The activated partial thromboplastin time test market for instruments product type is estimated to account for $289.8 million by 2026 at a 7.2% CAGR.

The market for point-of-care testing is projected to experience significant growth; it is anticipated to generate a revenue of $83.6 million by 2026 and is growing at a 7.7% CAGR. This growth is because of an increase in the number of point-of-care testing centers along with an increase in the population with age group above 60. The hospitals segment held the largest activated partial thromboplastin time test market size in 2018; it is estimated to reach $217.6 million by 2026, increasing at a growth rate of 6.5%. This is because of the growing usage of thromboplastin time test devices in the hospitals sector to treat patients for the analysis of hematological.

Asia-Pacific market will witness the highest growth rate of 7.3% CAGR and is expected to register a revenue of $143.1 million by 2026. This growth is attributed to swift progress in healthcare along with people preferring the point of care diagnosis of hospitals. Due to this swift growth, the Asia-Pacific market is predicted to grow during the forecast time. The global activated partial thromboplastin time test market was dominated by Europe, it was registered for majority of the activated partial thromboplastin market share, which was 30.0% in 2018. This growth is owing to the presence of upgraded diagnostic infrastructure in Europe. The market for North America region is expected to generate a revenue of $156.3 million by the end of 2026 with a CAGR of 6.7% during the projected time period.

Connect with Our Analyst to Contextualize Our Insights for Your Business: https://www.researchdive.com/connect-to-analyst/79

Top gaining participants in the activated partial thromboplastin time test market are Bio-Rad Laboratories, Inc., ThermoFisher, Abbott, bioMérieux, Inc., Danaher, Hoffmann-La Roche Ltd, Beckman Coulter, Inc., Takara Bio Inc., HORIBA, Ltd., Ortho Clinical Diagnostics and Siemens Healthcare Private Limited. These participants are continuously increasing their efforts to improve the product performance and introducing new technologies to gain the largest market share in the overall activated partial thromboplastin time test industry.

Contact Us:

Home

Friday, July 30, 2021

North America 3D Cell Culture market size will cross $4,019.1 million by 2026, increasing at a healthy CAGR of 28.1%.

For More Detail Insights, Download FREE Sample Copy of the Report at: https://www.researchdive.com/download-sample/75

Connect with Our Analyst to Contextualize Our Insights for Your Business: https://www.researchdive.com/connect-to-analyst/75

Download FREE Sample Copy of the Report at: https://www.researchdive.com/download-sample/79

Connect with Our Analyst to Contextualize Our Insights for Your Business: https://www.researchdive.com/connect-to-analyst/79